WO2005094420A3 - Materials and methods for treatment of inflammatory and cell proliferation disorders - Google Patents

Materials and methods for treatment of inflammatory and cell proliferation disorders Download PDF

Info

Publication number
WO2005094420A3
WO2005094420A3 PCT/US2005/004954 US2005004954W WO2005094420A3 WO 2005094420 A3 WO2005094420 A3 WO 2005094420A3 US 2005004954 W US2005004954 W US 2005004954W WO 2005094420 A3 WO2005094420 A3 WO 2005094420A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory
cell proliferation
agent
treatment
proliferation disorders
Prior art date
Application number
PCT/US2005/004954
Other languages
French (fr)
Other versions
WO2005094420A2 (en
Inventor
Shyam S Mohapatra
Original Assignee
Univ South Florida
Shyam S Mohapatra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida, Shyam S Mohapatra filed Critical Univ South Florida
Priority to EP05756620A priority Critical patent/EP1727556A2/en
Priority to CA002559853A priority patent/CA2559853A1/en
Priority to AU2005227870A priority patent/AU2005227870A1/en
Publication of WO2005094420A2 publication Critical patent/WO2005094420A2/en
Publication of WO2005094420A3 publication Critical patent/WO2005094420A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

The present invention pertains to methods for treatment of inflammatory and cell proliferation disorders, such as cancer, by administering an agent that reduces atrial natriuretic peptide receptor-A (NPR-A) activity. In one aspect, the invention concerns a method for treatment of inflammatory and cell proliferation disorders, such as cancer, by administration of an effective amount of natriuretic hormone peptide (NP), or a polynucleotide encoding NP and an operably-linked promoter sequence. In another aspect, the present invention includes a pharmaceutical composition comprising an agent that reduces the activity of atrial natriuretic peptide receptor-A (NPR-A), and an anti-cancer agent. In another aspect, the present invention further concerns a method for identifying an agent useful for treating an inflammatory or cell proliferation disorder, comprising determining whether the agent reduces the activity of atrial natriuretic peptide receptor-A (NPR-A).
PCT/US2005/004954 2004-02-17 2005-02-17 Materials and methods for treatment of inflammatory and cell proliferation disorders WO2005094420A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05756620A EP1727556A2 (en) 2004-02-17 2005-02-17 Materials and methods for treatment of inflammatory and cell proliferation disorders
CA002559853A CA2559853A1 (en) 2004-02-17 2005-02-17 Materials and methods for treatment of inflammatory and cell proliferation disorders
AU2005227870A AU2005227870A1 (en) 2004-02-17 2005-02-17 Materials and methods for treatment of inflammatory and cell proliferation disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52107204P 2004-02-17 2004-02-17
US60/521,072 2004-02-17

Publications (2)

Publication Number Publication Date
WO2005094420A2 WO2005094420A2 (en) 2005-10-13
WO2005094420A3 true WO2005094420A3 (en) 2006-02-16

Family

ID=35064353

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/004954 WO2005094420A2 (en) 2004-02-17 2005-02-17 Materials and methods for treatment of inflammatory and cell proliferation disorders

Country Status (5)

Country Link
US (2) US20050272650A1 (en)
EP (1) EP1727556A2 (en)
AU (1) AU2005227870A1 (en)
CA (1) CA2559853A1 (en)
WO (1) WO2005094420A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118888B2 (en) * 2001-09-28 2006-10-10 University Of South Florida Board Of Trustees Gene expression vaccine
AU2003224650A1 (en) * 2002-03-02 2003-09-16 University Of South Florida A method for treating allergic disease and asthma by recombinant adenovirus-and adeno-associated virus-mediated ifn-gamma gene
US7354908B2 (en) * 2002-04-30 2008-04-08 University Of South Florida Materials and methods for prevention and treatment of RNA viral diseases
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
AU2003268531A1 (en) 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
AU2003270427A1 (en) * 2002-09-06 2004-03-29 University Of South Florida Cellular delivery of natriuretic peptides
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
CA2516188C (en) * 2003-02-14 2012-04-17 University Of South Florida Chitosan-derivatives for gene delivery and expression
WO2004076664A2 (en) * 2003-02-21 2004-09-10 University Of South Florida Vectors for regulating gene expression
US7488713B2 (en) * 2004-03-18 2009-02-10 University Of South Florida Cancer treatment using C-type natriuretic peptides
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
EP1673465A4 (en) * 2003-09-29 2008-04-30 Biosite Inc Methods and compositions for the diagnosis of sepsis
EP1689414A4 (en) 2003-12-04 2009-04-08 Univ South Florida Res Foundat Polynucleotides for reducing respiratory syncytial virus gene expression
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
CA2559853A1 (en) 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
WO2005105136A1 (en) * 2004-04-27 2005-11-10 University Of South Florida Nanogene therapy for cell proliferation disorders
WO2007070175A2 (en) * 2005-12-09 2007-06-21 Oregon Health & Science University Natriuretic peptide related fragment in cardiovascular disease
CA2656990A1 (en) * 2006-04-28 2007-11-08 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
US7825092B2 (en) * 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
US8415096B2 (en) 2007-05-23 2013-04-09 University Of South Florida Micro-RNAs modulating immunity and inflammation
JP5395794B2 (en) * 2007-09-11 2014-01-22 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Use of galanin peptides as therapeutic agents
WO2009039981A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US9808512B2 (en) * 2007-12-28 2017-11-07 Kalos Therapeutics Anti-cell proliferative compounds and methods of use
WO2011153531A1 (en) * 2010-06-04 2011-12-08 University Of South Florida Method of treating skeletal dysplasias using vessel dilator
US9018168B2 (en) 2010-08-12 2015-04-28 Madeleine Pharmaceuticals Pty Ltd Therapeutic method for treating congestive heart failure
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
KR101969526B1 (en) * 2011-02-28 2019-04-17 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 Medicinal agent for inhibiting metastasis of malignant tumor
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
WO2013033675A1 (en) 2011-09-02 2013-03-07 Medtronic, Inc. Chimeric natriuretic peptide compositions and methods of preparation
CA2853204A1 (en) * 2011-12-16 2013-06-20 Kalos Therapeutics, Inc. Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
US20150315259A1 (en) * 2012-03-19 2015-11-05 Madeleine Phamaceuticals Pty Ltd Method of producing a recombinant peptide
WO2014160211A1 (en) * 2013-03-13 2014-10-02 Isis Pharmaceuticals, Inc. Modulation of inflammatory responses by c-reactive protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073628A1 (en) * 2001-03-29 2003-04-17 Kunwar Shailubhai Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5449751A (en) 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
US5691310A (en) * 1987-09-29 1997-11-25 Vesely; David L. Methods of treatment using proANF peptides
CA1339210C (en) * 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5043164A (en) 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5144019A (en) 1989-06-21 1992-09-01 City Of Hope Ribozyme cleavage of HIV-I RNA
US5272262A (en) 1989-06-21 1993-12-21 City Of Hope Method for the production of catalytic RNA in bacteria
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5705187A (en) 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5625056A (en) 1992-05-26 1997-04-29 Biolog Life Science Institute Derivatives of cyclic guanosine-3',5'-monophosphorothioate
JP3351476B2 (en) 1993-01-22 2002-11-25 三菱化学株式会社 Phospholipid derivatives and liposomes containing the same
DE4318387A1 (en) * 1993-06-03 1994-12-08 Bayer Ag Recombinant Foamy Virus vectors for medical and diagnostic applications and methods for producing recombinant Foamy Virus vectors
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
EP1253199A1 (en) 1993-09-02 2002-10-30 Ribozyme Pharmaceuticals, Inc. Abasic moieties containing enzymatic nucleic acids
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5583101A (en) 1994-07-15 1996-12-10 Harvard College Use of nitrogen oxide species and adducts to inhibit skeletal muscle contraction
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5602143A (en) 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
US5817856A (en) 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
US6184037B1 (en) * 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
US6028055A (en) * 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
US5858694A (en) 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US6013630A (en) 1997-08-21 2000-01-11 Curagen Corporation Atrial natriuretic factor mutants and ischemic stroke
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1096941B1 (en) * 1998-05-07 2005-08-10 University Of South Florida Bone marrow cells as a source of neurons for brain and spinal cord repair
US6194995B1 (en) 1998-07-31 2001-02-27 Buster West Gates Article dispenser
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
WO2004011498A2 (en) 2002-07-31 2004-02-05 Conjuchem Inc. Long lasting natriuretic peptide derivatives
US6558695B2 (en) * 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
JP2003526367A (en) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド RNA interference method and RNA interference composition
CA2404890C (en) 2000-03-30 2013-11-19 Whitehead Institute For Biomedical Research Rna sequence-specific mediators of rna interference
JP4237375B2 (en) * 2000-03-31 2009-03-11 アスビオファーマ株式会社 Pharmaceutical composition used for treatment or prevention of ischemic disease
US7678391B2 (en) 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20100305186A1 (en) 2000-05-30 2010-12-02 Johnson & Johnson Research Pty Limited Methods for mediating gene suppression
JP2004509079A (en) * 2000-08-02 2004-03-25 セラテクノロジーズ・インコーポレーテッド Modified biological peptides with increased potency
WO2002030470A1 (en) 2000-10-13 2002-04-18 Johns Hopkins University Methods and compositions for nucleic acid delivery
WO2002036142A2 (en) 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
JP2005503779A (en) 2001-06-10 2005-02-10 アイアールエム，エルエルシー Molecular signature of highly lethal cancer
CA2474283A1 (en) * 2002-02-07 2003-08-14 Yissum Research Development Company Of The Hebrew University In Jerusale M Amino acid sequences capable of facilitating penetration across a biological barrier
US7354908B2 (en) 2002-04-30 2008-04-08 University Of South Florida Materials and methods for prevention and treatment of RNA viral diseases
CA2430889A1 (en) * 2002-06-19 2003-12-19 Bayer Corporation Stabilization of brain natriuretic peptide (bnp) in blood samples, methods and compositions related thereto
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
AU2003270427A1 (en) * 2002-09-06 2004-03-29 University Of South Florida Cellular delivery of natriuretic peptides
AU2003268531A1 (en) 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
US20080214437A1 (en) 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
KR20050084607A (en) 2002-09-28 2005-08-26 매사추세츠 인스티튜트 오브 테크놀로지 Influenza therapeutic
AU2003297583B2 (en) * 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
KR20050088196A (en) * 2002-12-19 2005-09-02 알자 코포레이션 Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
WO2004069181A2 (en) * 2003-02-03 2004-08-19 Pharmacia Corporation Composition for the treatment of intraocular pressure
US8206704B2 (en) 2003-02-10 2012-06-26 Thomas Jefferson University Use of GCC ligands
CA2516188C (en) 2003-02-14 2012-04-17 University Of South Florida Chitosan-derivatives for gene delivery and expression
US6943147B2 (en) * 2003-03-19 2005-09-13 University Of South Florida Cancer treatment using proANP peptides
US7488713B2 (en) * 2004-03-18 2009-02-10 University Of South Florida Cancer treatment using C-type natriuretic peptides
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7445933B2 (en) * 2003-07-16 2008-11-04 Abbott Laboratories, Inc. Stable calibrators or controls for measuring human natriuretic peptides
US7291501B2 (en) * 2003-07-16 2007-11-06 Abbott Laboratories Stable compositions for measuring human natriuretic peptides
CA2559853A1 (en) 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US8759317B2 (en) * 2004-03-18 2014-06-24 University Of South Florida Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)
WO2005105136A1 (en) 2004-04-27 2005-11-10 University Of South Florida Nanogene therapy for cell proliferation disorders
WO2006026536A2 (en) 2004-08-26 2006-03-09 University Of South Florida Method of treatment of cancer using guanosine 3’, 5’ cyclic monophosphate (cyclic gmp)
US20060205642A1 (en) 2005-03-08 2006-09-14 Vesely David L Oral methods of treatment using proANF peptides
WO2007086923A2 (en) 2005-05-23 2007-08-02 University Of South Florida Controlled and sustained gene transfer mediated by thiol-modified polymers
CA2656990A1 (en) 2006-04-28 2007-11-08 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
WO2007130672A2 (en) 2006-05-05 2007-11-15 University Of South Florida Urodilatin cancer treatment
US7825092B2 (en) 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073628A1 (en) * 2001-03-29 2003-04-17 Kunwar Shailubhai Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIEMER AK AND VOLLMAR AM.: "Autocrine Regulation of Inducible Nitric-oxide Synthase in Macrophages by Atrial Natriuretic Peptide.", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 273, no. 22, May 1998 (1998-05-01), pages 13444 - 13451, XP002993655 *
VESELY DL ET AL: "Atrial Natriuretic Peptides in Pathophysiological Disease.", CARDIOVASCULAR RESEARCH., vol. 51, 2001, pages 647 - 658, XP002982441 *

Also Published As

Publication number Publication date
AU2005227870A1 (en) 2005-10-13
US20050272650A1 (en) 2005-12-08
AU2005227870A2 (en) 2005-10-13
CA2559853A1 (en) 2005-10-13
WO2005094420A2 (en) 2005-10-13
EP1727556A2 (en) 2006-12-06
US20090176706A1 (en) 2009-07-09
US8148114B2 (en) 2012-04-03

Similar Documents

Publication Publication Date Title
WO2005094420A3 (en) Materials and methods for treatment of inflammatory and cell proliferation disorders
ATE314062T1 (en) COMPOSITIONS FOR DELIVERING CORTISOL ANTAGONISTS
WO2007113648A3 (en) Ctla4 antibody combination therapy
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
WO2012112626A3 (en) Compositions, devices and methods of use thereof for the treatment of cancers
MX2009003093A (en) Compositions and methods relating to glucagon receptor antibodies.
Hammers et al. Controlled release of IGF‐I from a biodegradable matrix improves functional recovery of skeletal muscle from ischemia/reperfusion
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
WO2004091375A3 (en) Epha2 and non-neoplastic hyperproliferative cell disorders
WO2012075184A3 (en) Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
NZ562436A (en) Toll-like receptor 14 (TLR14) and use thereof
WO2008061011A3 (en) Intra-vascular kidney gene therapy with plasmid encoding bmp-7
WO2007147011A8 (en) Polynucleotide therapy
ZA200810124B (en) Pharmaceutical combination comprising 3-(3-dimethyl-amino-1-ethyl-2-methyl-propyl)-phenol and Paracetamol
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2005037211A3 (en) Methods and compositions for the treatment of neurological disease
WO2010099139A3 (en) Combination of an either an anti-igf-ir- antibody or an igf binding protein and a small molecule igf-ir kinease inhibitor
WO2014006502A8 (en) Protozoan variant-specific surface proteins (vsp) as carriers for oral drug delivery
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
MY157947A (en) Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
MX366347B (en) Isolating traffic-enhancing mutants of drug delivery protein.
WO2009108706A3 (en) Methods for inhibiting six 1 and eya proteins
WO2008010986A3 (en) Methods of modulating angiogenesis
Yang et al. The effect of cathepsin K inhibitor on osteoclastic activity compared to alendronate and enamel matrix protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2559853

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005227870

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005756620

Country of ref document: EP

Ref document number: 7013/DELNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005227870

Country of ref document: AU

Date of ref document: 20050217

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005227870

Country of ref document: AU

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005756620

Country of ref document: EP